EQRX · Eqrx, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $19.73M | $43.57M | $70.93M | - | $56.27M | $47.30M | $53.43M | - | - | - |
| SG&A | $23.40M | $21.48M | $27.28M | - | $34.09M | $31.79M | $10.28M | - | $2.13M | $150.9K |
| Total Operating Expenses | $101.55M | $91.84M | $101.80M | - | $90.37M | $79.09M | $26.96M | - | - | - |
| D&A | - | - | $188.0K | - | $300.0K | $300.0K | $289.0K | - | - | - |
| Operating Income | ($101.55M) | ($91.84M) | ($101.80M) | - | ($90.37M) | ($79.09M) | ($26.96M) | - | ($2.18M) | ($199.7K) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | - | $0 | $0 | $0 | - | - | - |
| Net Income | ($82.63M) | ($72.96M) | ($82.55M) | - | ($85.09M) | ($82.55M) | ($26.82M) | - | $6.54M | ($31.80M) |
| EPS - Basic | ($0.17) | ($0.15) | ($0.17) | - | ($0.12) | ($0.17) | $0.04 | - | - | - |
| EPS - Diluted | ($0.17) | ($0.15) | ($0.17) | - | ($0.12) | ($0.11) | ($0.09) | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $315.68M | $247.50M | $368.36M | $494.14M | $998.02M | $864.44M | $1.62B | $1.68B | $2.09M | $1.18M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.10M | $6.59M | $20.73M | $19.95M | $14.06M | $13.02M | $7.32M | $7.64M | $21.3K | $44.0K |
| Current Assets | $1.24B | $1.28B | $1.35B | $1.43B | $1.52B | $1.59B | $1.66B | $1.71B | $2.17M | $1.33M |
| Total Assets | $1.24B | $1.31B | $1.38B | $1.46B | $1.54B | $1.61B | $1.67B | $1.73B | $554.19M | $553.34M |
| Current Liabilities | $65.79M | $56.82M | $59.88M | $51.92M | $62.66M | $55.26M | $56.64M | $39.65M | $2.12M | $198.5K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $69.37M | $63.08M | $69.64M | $66.15M | $143.45M | $133.78M | $125.54M | $214.60M | $74.36M | $81.12M |
| Stockholders' Equity | $1.17B | $1.25B | $1.31B | $1.39B | $1.40B | $1.47B | $1.55B | $1.51B | ($72.17M) | $5.00M |
| Retained Earnings | ($765.73M) | ($683.10M) | ($610.14M) | ($527.59M) | ($505.41M) | ($420.32M) | ($337.77M) | ($358.50M) | ($72.17M) | ($31.84M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($85.55M) | - | - | - | ($23.52M) | - | - | - |
| Investing Cash Flow | - | - | ($40.36M) | - | - | - | ($43.0K) | - | - | - |
| Financing Cash Flow | - | - | $127.0K | - | - | - | $71.26M | - | - | - |
| CapEx | - | - | $444.0K | - | - | - | $43.0K | - | - | - |
| Free Cash Flow | - | - | ($85.99M) | - | - | - | ($23.56M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 1.04 | - | - | - | 0.88 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.7% | -5.6% | -6.0% | - | -5.5% | -5.1% | -1.6% | - | 1.2% | -5.7% |
| Return on equity | -7.1% | -5.8% | -6.3% | - | -6.1% | -5.6% | -1.7% | - | -9.1% | -636.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 18.78 | 22.60 | 22.63 | 27.51 | 24.32 | 28.74 | 29.23 | 43.04 | 1.03 | 6.70 |
| Quick ratio | 18.78 | 22.60 | 22.63 | 27.51 | 24.32 | 28.74 | 29.23 | 43.04 | 1.03 | 6.70 |
| Cash ratio | 4.80 | 4.36 | 6.15 | 9.52 | 15.93 | 15.64 | 28.66 | 42.34 | 0.98 | 5.93 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.06 | 1.05 | 1.05 | 1.05 | 1.10 | 1.09 | 1.08 | 1.14 | -7.68 | 110.67 |
| Liabilities / Assets | 0.06 | 0.05 | 0.05 | 0.05 | 0.09 | 0.08 | 0.07 | 0.12 | 0.13 | 0.15 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -12.4% | -16.1% | -277.6% | - | -4040.8% | -39513.5% | - | - | - | - |
| Net income growth (YoY) | 2.9% | 11.6% | -207.8% | - | - | -159.5% | -73538.7% | - | - | - |
| EPS growth (YoY) | -41.7% | -36.4% | -88.9% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -264.9% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -16.4% | -15.3% | -15.1% | -8.3% | - | 29390.0% | - | 214.2% | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing EQRx against the 5 most active filers in the same SIC group.